Back to companies

Denali Therapeutics Inc: Premium Databases

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Denali Therapeutics Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Denali Therapeutics Insights data

Headline Published Journalists
Showing 3 of 3 results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 04 Nov 2021 Lorem
LoA Update: Sanofi/Denali multiple sclerosis candidate bumps up chances for further study after completed Phase I trial 04 Nov 2021 William Newton
F-Star works CRO Medpace for Phase I bispecific antibody study, anticipates data in 2Q/3Q19, exec says 10 Aug 2018 Manasi Vaidya
Gamida Cell initiates USD 50m financing to complete Phase III cell therapy in blood cancers – CEO 20 Apr 2016 Alissa Fleck
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Gain a 360-degree view of Denali Therapeutics Inc and make more informed decisions for your business
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer